BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23730209)

  • 21. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
    Agnihotri N; Mehta K
    Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods to assess the activation of the alternative (noncanonical) NF-κB pathway by non-death TNF receptors.
    Remouchamps C; Dejardin E
    Methods Mol Biol; 2015; 1280():103-19. PubMed ID: 25736746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
    Brown KD
    Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
    Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
    Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transglutaminase 2 modulation of NF-κB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury.
    Feola J; Barton A; Akbar A; Keillor J; Johnson GVW
    Brain Res; 2017 Aug; 1668():1-11. PubMed ID: 28522262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response.
    Ghanta KS; Pakala SB; Reddy SD; Li DQ; Nair SS; Kumar R
    J Biol Chem; 2011 Mar; 286(9):7132-8. PubMed ID: 21156794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NF-κB Participates in the Stem Cell Phenotype of Ovarian Cancer Cells.
    Gonzalez-Torres C; Gaytan-Cervantes J; Vazquez-Santillan K; Mandujano-Tinoco EA; Ceballos-Cancino G; Garcia-Venzor A; Zampedri C; Sanchez-Maldonado P; Mojica-Espinosa R; Jimenez-Hernandez LE; Maldonado V
    Arch Med Res; 2017 May; 48(4):343-351. PubMed ID: 28886875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.
    Mann AP; Verma A; Sethi G; Manavathi B; Wang H; Fok JY; Kunnumakkara AB; Kumar R; Aggarwal BB; Mehta K
    Cancer Res; 2006 Sep; 66(17):8788-95. PubMed ID: 16951195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
    Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
    Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide.
    Telci D; Collighan RJ; Basaga H; Griffin M
    J Biol Chem; 2009 Oct; 284(43):29547-58. PubMed ID: 19657147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase.
    Khanna M; Chelladurai B; Gavini A; Li L; Shao M; Courtney D; Turchi JJ; Matei D; Meroueh S
    Mol Cancer Ther; 2011 Apr; 10(4):626-36. PubMed ID: 21330459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A TNF-p100 pathway subverts noncanonical NF-κB signaling in inflamed secondary lymphoid organs.
    Mukherjee T; Chatterjee B; Dhar A; Bais SS; Chawla M; Roy P; George A; Bal V; Rath S; Basak S
    EMBO J; 2017 Dec; 36(23):3501-3516. PubMed ID: 29061763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transglutaminase 2 regulates osteoclast differentiation via a Blimp1-dependent pathway.
    Kim WS; Kim H; Jeong EM; Kim HJ; Lee ZH; Kim IG; Kim HH
    Sci Rep; 2017 Sep; 7(1):10626. PubMed ID: 28878266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-κB noncanonical and canonical pathway activation.
    Farhana L; Dawson MI; Murshed F; Fontana JA
    Cell Death Differ; 2011 Jan; 18(1):164-73. PubMed ID: 20671747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classical NF-kappaB activation negatively regulates noncanonical NF-kappaB-dependent CXCL12 expression.
    Madge LA; May MJ
    J Biol Chem; 2010 Dec; 285(49):38069-77. PubMed ID: 20923761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland.
    Demicco EG; Kavanagh KT; Romieu-Mourez R; Wang X; Shin SR; Landesman-Bollag E; Seldin DC; Sonenshein GE
    Mol Cell Biol; 2005 Nov; 25(22):10136-47. PubMed ID: 16260626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
    Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
    Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion.
    Mangala LS; Arun B; Sahin AA; Mehta K
    Mol Cancer; 2005 Sep; 4():33. PubMed ID: 16153302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.
    Agnihotri N; Kumar S; Mehta K
    Breast Cancer Res; 2013 Feb; 15(1):202. PubMed ID: 23673317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling.
    Wang Z; Collighan RJ; Pytel K; Rathbone DL; Li X; Griffin M
    J Biol Chem; 2012 Apr; 287(16):13063-83. PubMed ID: 22298777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.